The broadest insurance coverage of any gonadotropin11
MENOPUR is covered by 90% of private insurance plans11
Coverage as of 6/25. Please note: Subject to change based on individual plan coverage.
Check the member’s benefits for more details.
MENOPUR is a prescription medicine for the development of multiple follicles in patients in an Assisted Reproductive Technology (ART) program.
MENOPUR
The essential choice
for quality
The only FDA-approved gonadotropin providing hCG-driven LH
activity and highly purified, naturally occurring FSH
in a 1:1 ratio1-6
clinical trials +
The MENOPUR difference
The only FDA-approved gonadotropin providing hCG-driven LH activity
and highly purified, naturally occurring FSH in a 1:1 ratio5,6
FSH
follicle-stimulating hormone
hCG-Driven LH Activity
luteinizing hormone
hCG=human chorionic gonadotropin.
Demonstrated safety profile
vs. rFSH in large clinical studies.
The most common adverse reactions (≥2%) include: abdominal cramps; abdomen enlarged; abdominal pain; headache; injection site pain and reaction; injection site inflammation; OHSS.6
The safety profile was similar with MENOPUR
and rFSH1,2
and rFSH1,2
Most common adverse events in Study 11 (occurring in over 0.3% of participants)
| Adverse Event | MENOPUR (n=373) | rFSH (n=354) |
|---|---|---|
| Ovarian hyperstimulation | 7.0% | 5.1% |
| Abdominal pain | 6.4% | 7.1% |
| Inflammation at injection site | 4.8% | 3.4% |
| Pain at injection site | 4.6% | 3.7% |
| Headache | 3.8% | 2.8% |
| Enlarged abdomen | 2.7% | 0.6% |
| Nausea | 1.9% | 0.3% |
| Reaction at injection site | 1.3% | 0.8% |
Most common adverse events in Study 22 (occurring in over 2.0% of participants)
| Adverse Event | MENOPUR (n=363) | rFSH (n=368) |
|---|---|---|
| Abortion | 9% | 10% |
| Pelvic pain | 6% | 6% |
| Headache | 5% | 5% |
| Post-procedural pain | 3% | 4% |
| Ovarian hyperstimulation syndrome | 4% | 3% |
| Nausea | 2% | 4% |
| Abdominal distension | 2% | 3% |
Please see additional Important Safety Information below.
rFSH=recombinant follicle-stimulating hormone; OHSS=ovarian hyperstimulation syndrome.
The journey starts with 225 IU of MENOPUR6
Each vial contains 75 IU of FSH and
hCG-driven LH activity5,6
IMPORTANT SAFETY INFORMATION
- MENOPUR is contraindicated in women who have: a high FSH level indicating primary ovarian failure, presence of uncontrolled non-gonadal endocrinopathies, tumors of the pituitary gland or hypothalamus, sex hormone dependent tumors of the reproductive tract and accessory organs, abnormal uterine bleeding of undetermined origin, ovarian cysts or enlargement of undetermined origin, not due to polycystic ovary syndrome, or prior hypersensitivity to menotropins or MENOPUR. MENOPUR is not indicated in women who are pregnant and may cause fetal harm when administered to a pregnant woman.
- MENOPUR should only be used by physicians who are thoroughly familiar with infertility problems. MENOPUR is a potent gonadotropic substance capable of causing Ovarian Hyperstimulation Syndrome (OHSS), with or without pulmonary or vascular complications, in women undergoing therapy for infertility. Ovarian torsion has been reported after gonadotropin treatment. Serious pulmonary conditions and thromboembolic events have been reported with MENOPUR. There have been infrequent reports of ovarian neoplasms with MENOPUR. Multiple pregnancies, spontaneous abortion, congenital malformations and ectopic pregnancies have occurred following treatment with MENOPUR.
- The most common adverse reactions (≥2%) in ART include: abdominal cramps; abdomen enlarged; abdominal pain; headache; injection site pain and reaction; injection site inflammation; OHSS.
INDICATION FOR USE
- MENOPUR® (menotropins for injection), administered subcutaneously, is indicated for the development of multiple follicles and pregnancy in the ovulatory patients participating in an Assisted Reproductive Technology (ART) program.
You are encouraged to report negative side effects of prescription drugs to FDA.
Visit www.FDA.gov/medwatch, or call 1.800.FDA.1088.
Please see full Prescribing Information.
Please see Important Safety Information and Full Prescribing Information